Physiological characterization of an arginine vasopressin rat model of preeclampsia
- 7 November 2021
- journal article
- research article
- Published by Taylor & Francis in Systems Biology in Reproductive Medicine
- Vol. 68 (1) , 55-69
Abstract
Rodent models have contributed greatly to our understanding of preeclampsia (PE) progression in humans, however to-date no model has been able to effectively replicate the clinical presentation of the disease. This study aimed to provide a thorough physiological characterization of the arginine vasopressin (AVP)-induced rat model of PE to determine its applicability in studying the pathophysiology of PE. Female Sprague Dawley rats (n = 24) were separated into four groups (n = 6 per group) viz., pregnant AVP, pregnant saline, non-pregnant AVP, and non-pregnant saline. All animals received a continuous dose of either AVP (150 ng/h) or saline via subcutaneous mini osmotic pumps for 18 days. Full physiological characterization of the model included measuring systolic and diastolic blood pressure, and collecting urine and blood samples for biochemical analysis. AVP infusion significantly increased blood pressure and urinary protein levels in the pregnant rats (p < 0.05). Biochemical markers measured, differed significantly in the AVP-treated vs the pregnant saline groups (p < 0.05). Placental and individual pup weight decreased significantly in the pregnant AVP vs pregnant saline group (p < 0.05). The physiological and hematological data confirm the usefulness of this rat model in the study of PE, since AVP-induced vasoconstriction increases peripheral resistance and successfully mimics the pathological changes associated with PE development in humans. Abbreviations: PE: preeclampsia; AVP: arginine vasopressin; ISSHP: International Society for the Study of Hypertension in Pregnancy; ACOG: American College of Obstetricians and Gynecologists; RUPP: reduced uterine perfusion pressure; sFlt-1: soluble fms-like tyrosine kinase; VEGF: vascular endothelial growth factor; PlGF: placental growth factor; AVP: arginine vasopressin; PAVP: pregnant AVP-treated; PS: pregnant saline; GD: gestational day; ALT: alanine transaminase; NAVP: non-pregnant AVP-treated; NS: non-pregnant saline; AST: aspartate aminotransferase; HDL: high-density lipoprotein; RBC: red blood cell; RAAS: renin-angiotensin aldosterone system; HELLP: hemolysis, elevated liver enzymes, low platelet.Keywords
Funding Information
- National Research Foundation (107236)
This publication has 83 references indexed in Scilit:
- Increased Placental Phospholipid Levels in Pre-Eclamptic PregnanciesInternational Journal of Molecular Sciences, 2013
- Copeptin and its potential role in diagnosis and prognosis of various diseasesBiochemia Medica, 2013
- Estimation of Lipid Profile in Subjects of PreeclampsiaThe Journal of Obstetrics and Gynecology of India, 2011
- Hyperfiltration Affects Accuracy of Creatinine eGFR MeasurementClinical Journal of the American Society of Nephrology, 2011
- Toxicological Pathology in the Rat PlacentaJournal of Toxicologic Pathology, 2011
- Vasopressin beyond water: implications for renal diseasesCurrent Opinion in Nephrology and Hypertension, 2010
- Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connectionsExpert Review of Cardiovascular Therapy, 2008
- A novel renal perspective of preeclampsia: a look from the podocyteNephrology Dialysis Transplantation, 2007
- Vasopressin: a new target for the treatment of heart failureAmerican Heart Journal, 2003
- Level of hydration and renal function in healthy humansKidney International, 2001